参麦注射液对大鼠糖尿病周围神经病变疗效的实验分析

[目的]观察参麦注射液对大鼠糖尿病周围神经病变的疗效,探讨其作用机制.[方法]采用链脲佐菌素(STZ)糖尿病(DM)大鼠模型,分为模型组、参麦注射液治疗Ⅰ组、治疗Ⅱ组、阳性对照药(消渴丸治疗)组,并设正常对照组.糖尿病大鼠造模成功后予参麦注射液早期干预,开始给药6周后将模型组和正常组比较神经电生理参数、血清抗神经节苷脂抗体(anti-GS-ab)水平,观察各组神经超微结构的变化.[结果]治疗后参麦组神经传导速度明显高于消渴丸组与模型组(P<0.05),参麦高剂量组优于低剂量组(P<0.05);治疗后参麦组血清anti-GS-ab水平明显低于其他各组(P<0.05),参麦高剂量组anti-GS-ab低于低剂量组(P<0.05).[结论]参麦注射液对大鼠糖尿病周围神经病变有良好的疗效,可能是通过调节自身免疫功能机制发挥作用.     

参芪扶正注射液对RAU大鼠外周血T细胞亚群的影响

目的：建立复发性口疮（RAU）大鼠动物模型，探讨参芪扶正注射液对RAU的免疫调节作用。方法：大鼠脊柱两侧注射大鼠口腔黏膜抗原乳化液，建模后将溃疡大鼠随机分为3组：对照组建模正常饮食水。参芪扶正注射液组大鼠按8ml／（kg·d）剂量灌胃，左旋咪唑组大鼠0．02g／（kg·d）剂量灌胃，均20d。分别于建模前，成模后用药前、给药后大鼠眼眶采血行免疫组化染色，CD4^＋．CD8^＋细胞计数并进行统计学分析。结果：实验大鼠于最后一次抗原注射6d后开始出现口腔溃疡。RAU大鼠CD4^＋、CD4^＋／CD8^＋细胞量较建模前降低。实验大鼠给药后，参芪扶正注射液组、左旋咪唑组外周血CD4^＋、CD4^＋／CD8^＋均有回升，较对照组有显著性差异（P〈0．05），参芪扶正注射液组与左旋咪唑组相比。差异无统计学意义。结论：参芪扶正注射液对RAU大鼠有一定的免疫调节作用,与左旋咪唑无明显差异。     

血栓通氯化钠注射液全身用药的过敏性、溶血性及刺激性实验*

[目的]考察血栓通氯化钠注射液对豚鼠的全身过敏作用,对家兔红细胞的体外溶血作用及对家兔血管的刺激作用.[方法]用豚鼠进行血栓通氯化钠注射液的全身用药的过敏性实验,用家兔进行溶血性和血管刺激实验.[结果]血栓通氯化钠注射液豚鼠注射给药不产生过敏反应,体外直接接触红细胞不产生溶血现象,连续7d家兔耳缘静脉注射给药,肉眼观察未见耳部血管有明显充血、水肿等刺激反应;病理组织学检查表明,本品对家兔耳缘静脉内膜、内皮组织及周围组织无致损伤作用和刺激性;本品单次或多次滴入家兔眼睛,对家兔眼结膜、角膜、虹膜等黏膜组织均无明显刺激作用.[结论]血栓通氯化钠注射液对豚鼠无过敏反应,无溶血及红细胞凝聚现象,对用药血管和眼也没有刺激性反应.     

地氯雷他定联合斯奇康治疗湿疹疗效观察

目的：探讨地氯雷他定联合斯奇康治疗湿疹的临床疗效。方法：将197例湿疹患者随机分为三组。治疗组67例：地氯雷他定5mg，口服，每日1次，斯奇康0．5mg，肌注，隔日1次；地氯雷他定组72例：地氯雷他定5mg，口服，每日1次；斯奇康组58例：斯奇康0．5mg，肌注，隔日1次。三组疗程均为36d，均于治疗后第18、36d复诊。结果：18d时三组疗效比较，治疗组与地氯雷他定组总显效率有显著性差异（P〈0．05）．治疗组与斯奇康组总显效率有显著性差异（P〈0．005），地氯雷他定组与斯奇康组总显效率差异无显著性（P〉0．05）；36d时三组疗效比较，治疗组与地氯雷他定组总显效率有显著性差异（P〈0．05），治疗组与斯奇康组总显效率有显著性差异（P〈0．05），地氯雷他定组与斯奇康组总显效率无显著性差异（P〉0．05）。结论：地氯雷他定联合斯奇康治疗湿疹．临床疗效显著。     

Intracytoplasmic Sperm Injection Fertilization Rate Does Not Depend on the Proportion of Round-headed Sperm,Small-acrosomal Sperm,or Morphologically Normal Sperm in Patients with Partial Globozoospermia

Background:

Generally, intracytoplasmic sperm injection (ICSI) may be the preferable method to treat partial globozoospermia, but whether there exist some correlations between ICSI fertilization rate and the proportion of round-headed sperm or morphologically normal sperm remains open. This study was to explore the correlation between ICSI fertilization rate and the sperm morphology in patients with partial globozoospermia.

Methods:

Thirty-four patients diagnosed with partial globozoospermia accepted the following assisted fertilization treatments – 2 cases accepted in-vitro fertilization (IVF) alone, 26 cases accepted ICSI alone, and 6 accepted split IVF/ICSI. Detailed morphological characteristics were described using Diff-Quik rapid staining. Sixty cases accepting IVF or ICSI treatment in our reproductive center were considered as the control group after being matched by relevant criteria. Fertilization rate, embryo quality, embryo implantation rate and clinical pregnancy rate were calculated.

Results:

Besides very high proportion of round-headed sperm, partial globozoospermia also showed very high proportion of small-acrosomal sperm and very low proportion of morphologically normal sperm. Fertilization rate of IVF (IVF alone plus split IVF) was very low in partial globozoospermia (25.4% ± 17.4%), but ICSI (ICSI alone plus split ICSI) achieved satisfying fertilization rate compared with the control group (66.2% ± 22.5% vs. 68.8% ± 29.4%, P > 0.05). In patients with partial globozoospermia, there were no correlations between ICSI fertilization rate and the proportion of round-headed sperm, small-acrosomal sperm, or morphologically normal sperm.

Conclusions:

There was high proportion of small-acrosomal sperm in partial globozoospermia. For patients with partial globozoospermia, ICSI is more preferable than IVF. ICSI fertilization rate does not depend on the proportion of round-headed sperm, small-acrosomal sperm, or morphologically normal sperm.     

A Rat Model of Striatonigral Degeneration Generated by Simultaneous Injection of 6-Hydroxydopamine into the Medial Forebrain Bundle and Quinolinic Acid into the Striatum

A double toxin-double lesion strategy is well-known to generate a rat model of striatonigral degeneration (SND) such as multiple system atrophy-parkinsonian type. However, with this model it is difficult to distinguish SND from Parkinson''s disease (PD). In this study, we propose a new rat model of SND, which is generated by simultaneous injection of 6-hydroxydopamine into the medial forebrain bundle and quinolinic acid into the striatum. Stepping tests performed 30 min after intraperitoneal L-dopa administration at 6 weeks post-surgery revealed an L-dopa response in the PD group but not the SND group. Apomorphine-induced rotation tests revealed no rotational bias in the SND group, which persisted for 2 months, but contralateral rotations in the PD group. MicroPET scans revealed glucose hypometabolism and dopamine transporter impairment on the lesioned striatum in the SND group. Tyrosine hydroxylase immunostaining in the SND group revealed that 74.7% of nigral cells on the lesioned side were lost after lesion surgery. These results suggest that the proposed simultaneous double toxin-double lesion method successfully created a rat model of SND that had behavioral outcomes, multitracer microPET evaluation, and histological aspects consistent with SND pathology. This model will be useful for future study of SND.     

喜炎平注射液抗Ⅱ型登革病毒作用的体内及体外实验研究

目的 分别通过体外和体内实验研究喜炎平注射液对Ⅱ型登革病毒（Dengue virus serotype 2, DENV2）的抗病毒作用。方法 体外实验以利巴韦林注射液作为阳性对照药物,分别以灭活、抑制进入、治疗性给药以及预防联合维持治疗的方式处理人肝癌细胞株HepG2细胞,在不同时相点收获上清和细胞,分别利用间接免疫荧光（indirect immunofluorescence assay, IFA）和实时荧光定量PCR（quantitative real-time PCR, qPCR）检测DENV2的病毒载量,从而评价喜炎平注射液的体外抗DENV2作用。体内实验以SCID小鼠为实验鼠,腹腔注射HepG2细胞,建立模型小鼠,腹腔注射感染DENV2,次日给予不同剂量（1、2、4 mg/只）的喜炎平注射液,连续给药4 d,部分小鼠于感染第6日取材,利用IFA检测实验鼠脾、肝及血清中病毒载量,并观察实验鼠的生存率。结果 体外实验显示,喜炎平注射液能够灭活DENV2,并抑制DENV2进入细胞,同时无论是治疗还是治疗联合预防给药,均可对DENV2的复制具有良好的抑制作用,即在病毒感染早期及晚期,喜炎平均可发挥抗病毒作用,且优于利巴韦林。进一步在体内实验中同样显示喜炎平具有较好的抗病毒作用,可以降低实验鼠脾、肝及血清中病毒载量,并可提高实验鼠的生存率。结论 喜炎平注射液具有明显的抗DENV2病毒的作用,可为DENV感染的治疗提供新的候选药物。     

脑络通胶囊联合丁苯酞治疗急性脑梗死的临床研究

目的探讨脑络通胶囊联合丁苯酞氯化钠注射液治疗急性脑梗死的临床疗效。方法选取2018年2月—2019年2月在朝阳市第二医院治疗的急性脑梗死患者94例,根据住院号分为对照组(47例)和治疗组(47例)。对照组患者静脉滴注丁苯酞氯化钠注射液,100 mL/次,2次/d;治疗组在对照组基础上给予脑络通胶囊,1.0 g/次,3次/d。两组患者均治疗2周。观察两组患者临床疗效,同时比较治疗前后两组患者NIHSS、MoCA、m RS和SF-36评分,血清血红素氧合酶1(HO1)、新蝶呤(Npt)、肽素(CP)、血小板激活因子(PAF)、亲环素A(CyPA)和可溶性肿瘤坏死因子相关凋亡诱导配体(sTRAIL)水平,亦及红细胞压积(HCT)、血浆黏度(PV)、全血黏度(WBV)、纤维蛋白原(FIB)、动态阻力(DR)、相对平均血流量(Qmean)、脑血管周围阻力(R)、平均血流速度(Vmean)和特性阻抗(ZCV)改变。结果治疗后,对照组临床有效率为80.85%,显著低于治疗组的97.87%,两组比较差异有统计学意义(P0.05)。治疗后,两组患者NIHSS评分和m RS评分均显著降低(P0.05),而MoCA评分和SF-36评分均明显升高(P0.05),且治疗组患者这些评分明显好于对照组(P0.05)。治疗后,两组患者血清HO1、Npt、CPP、PAF、CyPA、sTRAIL水平均明显降低(P0.05),且治疗组患者这些血清学指标明显低于对照组(P0.05)。治疗后,两组患者HCT、PV、WBV、FIB、ZCV和R水平均明显下降,而Qmean、DR和Vmean均显著升高(P0.05),且治疗组患者这些指标水平明显好于对照组(P0.05)。结论脑络通胶囊联合丁苯酞治疗急性脑梗死可促进神经功能恢复、血液流变学改善,以及提高生活质量。